Related Experiment Video

Updated: May 14, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Genotype-dependent response to combined levodopa/benserazide and trihexyphenidyl in pediatric genetic dystonia

Xiaolin Zhou1, Yu Li1, Xiangyang Luo1

  • 1Department of Pediatric Neurology, Sun Yat-Sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Brain & Development
|May 12, 2026
PubMed

Insights

Treatment response to levodopa/benserazide and trihexyphenidyl in pediatric genetic dystonia is genotype-dependent. PANK2 and other monogenic dystonia respond well, while channelopathies show minimal benefit, guiding therapy decisions.

Area of Science:

  • Pediatric Neurology
  • Genetics
  • Movement Disorders

Background:

  • Genetic factors significantly contribute to pediatric dystonia.
  • The influence of specific genotypes on treatment response to combined dopaminergic and anticholinergic therapy is not well understood.

Purpose of the Study:

  • To investigate whether treatment response to levodopa/benserazide and trihexyphenidyl combination therapy in pediatric genetic dystonia varies by genotype.
  • To compare treatment outcomes across different genetic subgroups of pediatric dystonia.

Main Methods:

  • A retrospective cohort study of 36 children with genetically confirmed dystonia.
  • Patients were classified into PANK2, channelopathy (SCN1A/SCN2A/SCN3A/SCN1B, KCNQ2), and other monogenic etiology subgroups.
  • Treatment involved levodopa/benserazide and trihexyphenidyl for 16 weeks, with outcomes assessed using BADS, GMFM-88, QUEST, and CP-QOL.

Main Results:

  • Treatment response demonstrated a clear genotype dependency.
  • PANK2 patients exhibited excellent improvement in dystonia and motor function.
  • Channelopathy patients showed minimal benefit, unlike other monogenic groups (p < 0.001).
  • Patients with status dystonicus responded excellently, irrespective of initial severity.

Conclusions:

  • Genotype is a critical determinant of treatment response in pediatric genetic dystonia.
  • Levodopa/benserazide and trihexyphenidyl combination therapy is highly effective for PANK2 and other monogenic dystonias, but less so for channelopathies.
  • Therapeutic strategies should be guided by genetic diagnosis rather than solely by disease severity.
Abstract

Keywords:
ChannelopathiesGenetic dystoniaPANK2levodopa/benserazidetrihexyphenidyl

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alterations in Muscle Tone ll01:12

Alterations in Muscle Tone ll

Alterations in muscle tone are common manifestations of neurological disorders and reflect dysfunction within different nervous system regions. Spasticity, paratonia, and dystonia represent distinct forms of hypertonia, each with unique mechanisms, clinical features, and diagnostic importance.CharacteristicsSpasticity happens from upper motor neuron lesions and is characterized by velocity-dependent resistance to passive movement. Clinical features include:Exaggerated deep tendon reflexesClonus...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...